Alzheimer’s Biomarkers For Disease Progression Will Be A Hard Road, Experts Say
This article was originally published in The Pink Sheet Daily
Executive Summary
A panel of experts discussing challenges in researching disease-progression biomarkers for Alzheimer’s agreed that the heterogeneity and evolving nature of the disease complicate the task and may require large panels of biomarkers – a potentially costly and invasive solution.
You may also be interested in...
The Conundrum Of Alzheimer’s Disease R&D
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.
Lilly Expands Bet on Tau By Buying Siemens’ Alzheimer’s Imaging Portfolio
The acquisition of a tau PET imaging portfolio from Siemens further expands Lilly’s Alzheimer’s program.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.